CYP2C93 Variant is Associated with Antidiabetes Efficacy of Gliclazide in Chinese Type 2 Diabetes Patients

Overview

Journal J Diabetes Investig

Specialty Endocrinology

Date 2016 May 17

PMID 27181593

Citations 10

Authors

Wotan Zeng

Yali Guo

Peixian Chen

Zhike Liu

Dafang Chen

Chunji Han

Affiliations

Soon will be listed here.

Abstract

Aims/introduction: The objective of the present study was to investigate the effects of CYP2C9*3 polymorphisms on the therapeutic response to gliclazide in type 2 diabetes patients.

Materials And Methods: A total of 746 incident type 2 diabetes patients were included in this study. After enrolment, patients went on 4-week gliclazide monotherapy. Fasting plasma glucose was measured before and after treatment. Hypoglycemia episodes and lifestyle information were collected by weekly follow up. Genotyping of rs1057910 was carried out using the single base primer extension method. The t-test, analysis of variance and chisquare-test were used to evaluate the effects of rs1057910 alleles on the therapeutic response to gliclazide.

Results: After the therapy, fasting plasma glucose decreased significantly from 11.2 ± 2.7 mmol/L to 8.0 ± 2.2 mmol/L (P < 0.001). Patients with AC/CC genotypes of rs1057910 had a greater reduction of fasting plasma glucose (3.6 vs 3.0 mmol/L, P < 0.001; 31.4 vs 24.5%, P < 0.001) and a higher rate of treatment success (54.7 vs 37.5%, P < 0.001; 51.4 vs 32.3%, P < 0.001; 71.6 vs 48.3%, P < 0.001 for criterion 1, 2 and 3, respectively).

Conclusions: The present study showed that the polymorphism at rs1057910 significantly affected the therapeutic response of gliclazide in type 2 diabetes mellitus patients. The risk allele is associated with a greater decrease of fasting blood glucose and a higher rate of treatment success with gliclazide monotherapy.

Citing Articles

Physiologically based pharmacokinetic (PBPK) modeling of gliclazide for different genotypes of CYP2C9 and CYP2C19.

Park H, Lee S, Kang P, Cho C, Jang C, Lee S Arch Pharm Res. 2025; .

PMID: 39760829 DOI: 10.1007/s12272-024-01528-8.

Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects.

Kang P, Cho C, Jang C, Lee S, Lee Y, Choi C Arch Pharm Res. 2023; 46(5):438-447.

PMID: 37097441 DOI: 10.1007/s12272-023-01448-z.

Identification and functional assessment of 10 CYP2C9 variants found in Chinese Han subjects.

Zhang Q, Qi Y, Wang S, Zhao F, Zou L, Zhou Q Front Endocrinol (Lausanne). 2023; 14:1139805.

PMID: 37008923 PMC: 10052410. DOI: 10.3389/fendo.2023.1139805.

Pharmacogenomics of sulfonylureas in type 2 diabetes mellitus; a systematic review.

Karkhaneh L, Tabatabaei-Malazy O, Bandarian F, Mohseni S, Larijani B J Diabetes Metab Disord. 2022; 21(1):863-879.

PMID: 35673432 PMC: 9167353. DOI: 10.1007/s40200-021-00908-x.

A pharmacogenetic pilot study of common genetic variant and sulfonylureas therapeutic response in type 2 diabetes mellitus patients.

Didari E, Sarhangi N, Afshari M, Aghaei Meybodi H, Hasanzad M J Diabetes Metab Disord. 2021; 20(2):1513-1519.

PMID: 34900803 PMC: 8630254. DOI: 10.1007/s40200-021-00894-0.

References

Elliot D, Suharjono , Lewis B, Gillam E, Birkett D, Gross A . Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. Br J Clin Pharmacol. 2007; 64(4):450-7. PMC: 2048545. DOI: 10.1111/j.1365-2125.2007.02943.x. View

Lee H, Lim M, Lee J, Jegal M, Kim D, Lee W . Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokinetics. J Clin Pharm Ther. 2011; 37(1):105-11. DOI: 10.1111/j.1365-2710.2010.01238.x. View

Suzuki K, Yanagawa T, Shibasaki T, Kaniwa N, Hasegawa R, Tohkin M . Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract. 2005; 72(2):148-54. DOI: 10.1016/j.diabres.2005.09.019. View

Aquilante C . Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Expert Rev Cardiovasc Ther. 2010; 8(3):359-72. PMC: 2860269. DOI: 10.1586/erc.09.154. View

Swen J, Wessels J, Krabben A, Assendelft W, Guchelaar H . Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus. Pharmacogenomics. 2010; 11(11):1517-23. DOI: 10.2217/pgs.10.121. View

Sartor G, Melander A, SCHERSTEN B . Serum glibenclamide in diabetic patients, and influence of food on the kinetics and effects of glibenclamide. Diabetologia. 1980; 18(1):17-22. DOI: 10.1007/BF01228296. View

Zeng W, Guo Y, Chen P, Liu Z, Chen D, Han C . CYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patients. J Diabetes Investig. 2016; 7(5):764-8. PMC: 5009140. DOI: 10.1111/jdi.12486. View

Kirchheiner J, Bauer S, Meineke I, Rohde W, Prang V, Meisel C . Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics. 2002; 12(2):101-9. DOI: 10.1097/00008571-200203000-00004. View

Ren Q, Han X, Tang Y, Zhang X, Zou X, Cai X . Search for genetic determinants of sulfonylurea efficacy in type 2 diabetic patients from China. Diabetologia. 2013; 57(4):746-53. DOI: 10.1007/s00125-013-3146-z. View

10.

Ragia G, Tavridou A, Elens L, van Schaik R, Manolopoulos V . CYP2C9*2 allele increases risk for hypoglycemia in POR*1/*1 type 2 diabetic patients treated with sulfonylureas. Exp Clin Endocrinol Diabetes. 2014; 122(1):60-3. DOI: 10.1055/s-0033-1361097. View

11.

Gokalp O, Gunes A, Cam H, Cure E, Aydin O, Tamer M . Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting. Eur J Clin Pharmacol. 2011; 67(12):1223-9. DOI: 10.1007/s00228-011-1078-4. View

12.

Ragia G, Petridis I, Tavridou A, Christakidis D, Manolopoulos V . Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics. 2009; 10(11):1781-7. DOI: 10.2217/pgs.09.96. View

13.

Becker M, Visser L, Trienekens P, Hofman A, van Schaik R, Stricker B . Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clin Pharmacol Ther. 2007; 83(2):288-92. DOI: 10.1038/sj.clpt.6100273. View

14.

Rendell M . The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs. 2004; 64(12):1339-58. DOI: 10.2165/00003495-200464120-00006. View

15.

Ghanayem B, Bell D, Zhang Z, Kaminsky L, Shenfield G, Miners J . The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 1996; 6(4):341-9. DOI: 10.1097/00008571-199608000-00007. View

16.

Manolopoulos V . Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice. Clin Chem Lab Med. 2007; 45(7):801-14. DOI: 10.1515/CCLM.2007.184. View

17.

Klen J, Dolzan V, Janez A . CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients. Eur J Clin Pharmacol. 2014; 70(4):421-8. DOI: 10.1007/s00228-014-1641-x. View

18.

Holstein A, Plaschke A, Ptak M, Egberts E, El-Din J, Brockmoller J . Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol. 2005; 60(1):103-6. PMC: 1884896. DOI: 10.1111/j.1365-2125.2005.02379.x. View

19.

Kirchheiner J, Brockmoller J, Meineke I, Bauer S, Rohde W, Meisel C . Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther. 2002; 71(4):286-96. DOI: 10.1067/mcp.2002.122476. View

20.

Niemi M, Cascorbi I, Timm R, Kroemer H, Neuvonen P, Kivisto K . Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther. 2002; 72(3):326-32. DOI: 10.1067/mcp.2002.127495. View